Trial name: EXPLORER

Status: Recruiting

 

Description: Avapritinib is an oral, investigational drug being studied as a potential treatment for people with advanced systemic mastocytosis (SM). Avapritinib is a potent and selective inhibitor of activated KIT, including D816V mutant KIT, the driver of disease in nearly all people with SM. EXPLORER is a Phase 1 clinical trial that is designed to test the safety and clinical activity of avapritinib in people with advanced SM.

 

Eligibility:

  • Group 1: People with aggressive SM (ASM)
  • Group 2: People with SM with an associated hematologic neoplasm (SM-AHN)
  • Group 3: People with mast cell leukemia (MCL)

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.clinicaltrials.gov (Identifier: NCT02561988).